SpiDex (Dexamethasone & Spironolactone) Shows Superior Results for Hospitalized COVID-19 Patients

A new COVID-19 drug cocktail is hailed as a possible treatment for the new SARS-CoV-2 variant of concern after producing evidence that the combination therapy can keep people out of intensive care units over current available medicines.  More specifically the cocktail demonstrates a four-fold increase in keeping COVID-19 patients out of the intensive care unit (ICU) according to the principal investigator Sir Christopher Edwards, former vice-chancellor of Newcastle University and formally representing Imperial College of London for this proof of concept study also involving a Ukrainian hospital. The cocktail includes both the corticosteroid dexamethasone and the heart failure medication spironolactone and is referred to as “SpiDex.”

Brief Overview

Published in several online news dailies including the British Telegraph, the actual trial site was based in a hospital Ukraine.  In this randomized controlled trial only 5.4% of the hospitalized patients on the “SpiDex regimen ended up in the ICU as compared to 19.6% of those patients given dexamethasone alone according to the study published in the peer reviewed Frontiers in Endocrinology.  This little noticed study showcase...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee